α-Ketoamides Keep Different Viruses from Multiplying

  • Author: ChemistryViews.org
  • Published: 04 March 2020
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Journal of Medicinal Chemistry/ACS Publications
  • Associated Societies: American Chemical Society (ACS), USA
thumbnail image: α-Ketoamides Keep Different Viruses from Multiplying

Antiviral drugs that target a variety of viruses, i.e., broad-spectrum antivirals, could be particularly useful to treat rare or new virus strains, such as the one currently causing the outbreak of COVID-19. This approach could be more commercially viable than developing a drug for every single disease caused by viruses and, thus, improve treatment options. To achieve broad activity, the drugs need a target that several viruses share. The very common enteroviruses, for example, depend on viral proteases to multiply. These proteases have similar active sites to the equivalent proteases in rarer coronaviruses, such as the SARS and MERS viruses, even though the viruses are very different overall.


Hong Liu, Shanghai Institute of Materia Medica, China, Rolf Hilgenfeld, Shanghai Institute of Materia Medica and University of Lübeck, Germany, and colleagues have developed α-ketoamides that could inhibit these proteases in coronaviruses and enteroviruses and, thus, prevent the replication of the viruses. The team used structure-based design, i.e., they analyzed crystal structures of the target proteases and of protease–inhibitor complexes. These structures were used to guide the optimization of the substituents at the α-ketoamides.


The researchers found that the best inhibitors have a γ-lactam derivative of glutamine and a cyclopentylmethyl or cyclohexylmethyl group next to the α-ketoamide unit. These inhibitors showed good activity against both enteroviruses and coronaviruses in cell cultures. The compounds showed only weak cytotoxicity. According to the team, due to the high similarity between the main proteases of the SARS virus and the new coronavirus that causes COVID-19, the developed inhibitors could also show antiviral activity against the new coronavirus.



Also of Interest

 

  • LitCovid
    Curated literature hub for tracking up-to-date scientific information about COVID-19
  • Many publishers and other entities have signed a joint statement to ensure that COVID-19 research findings and data are shared rapidly and openly

 

 

Article Views: 1113

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

1 Comments

Valeriy Bacherikov wrote:

possible structures for increased activities

The authors can modify the structure by introducing in molecule of inhibitor the non-natural amino acids, for example homo-phenylalanine instead of phenylalanine or others. Such a structural change often leads to a significant increase in protease inhibition, for example, in the case of inhibition of P. falciparum cysteine proteases. The corresponding molecules were synthesized and showed high inhibition activity. See DOI: 10.1002/cbdv.201700037

Tue Mar 24 15:50:56 UTC 2020

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)published by Wiley-VCH